礼来向逾40国监管机构提交Orforglipron申请 肥胖症药物有望于2026年第二季度在美获批

美股速递
Feb 26

礼来公司宣布,已向全球超过40个国家的药品监管机构提交了新型GLP-1受体激动剂Orforglipron的上市申请。这款备受关注的代谢疾病治疗药物,预计将在2026年第二季度获得美国食品药品监督管理局的审评结果,有望为肥胖症治疗领域带来新的突破。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10